Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Bevacizumab (Primary) ; Natural killer cell therapy Shenzhen Hank Bioengineering Institute (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 10 Sep 2019 Status changed from recruiting to completed.
- 12 Jan 2017 New trial record